Palmitoylethanolamide

Palmitoylethanolamide (PEA) is a naturally occurring fatty acid amide, belonging to the class of nuclear factor agonists. PEA has been demonstrated to bind to a receptor in the cell-nucleus (a nuclear receptor) and exerts a great variety of biological functions related to chronic pain and inflammation. The main target is thought to be the peroxisome proliferator-activated receptor alpha (PPAR-α).

History

PEA was identified in the 1950s as a therapeutic principle in egg yolk. In the 1990s, its anti-inflammatory properties were identified. PEA is currently under investigation in clinical trials for its potential therapeutic role in various diseases.

Pharmacology

PEA is an endogenous fatty acid amide and belongs to the class of nuclear factor agonists. PEA has been shown to have anti-inflammatory, analgesic, neuroprotective, and anticonvulsant properties.

Clinical significance

PEA has been suggested as a potential therapeutic agent in a variety of disorders, including neuropathic pain, neurodegenerative diseases, and inflammation.

See also

• Fatty acid amide
• Nuclear factor agonists
• Peroxisome proliferator-activated receptor alpha

External links

• PubMed articles on Palmitoylethanolamide

Palmitoylethanolamide Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski